Stay Alert for Safety Issues With Xeljanz and Other "JAK Inhibitors"

October 2019

Questions will pop up about the safety of "Janus kinase (JAK) inhibitors"...Xeljanz, Olumiant, and the newly approved Rinvoq.

There's an uptick in use of these specialty meds for rheumatoid arthritis and other autoimmune diseases...since they're taken orally.

Now there's a boxed warning about an increased risk of blood clots with Xeljanz (tofacitinib). Olumiant (baricitinib) and Rinvoq (upadacitinib) also carry this warning.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Look-Alike/Sound-Alike Stop Look-Alike/Sound-Alike Med Errors in Their Tracks
Influenza Know the Latest About Influenza Immunizations for 2019-2020
E-Cigarettes Help Extinguish E-Cigarette Use in Teens
Medicare Be Ready for Questions About 2020 Medicare Part D Changes
Pharmacy Practice Sort Through the Maze of Compression Stockings
Contraceptives Avoid Errors With Slynd, a New Oral Contraceptive
Pediatrics Victoza Will Be a New Option for Kids With Type 2 Diabetes
Antibiotics Update Profiles if Patients Get the Specialty Med Xenleta
Vaccines Expect Some, But Not All, Adults Over Age 26 to Get Gardasil 9
Immunosuppressives Stay Alert for Safety Issues With Xeljanz and Other "JAK Inhibitors"
Pharmacy Practice Use Strategies to Promote Teamwork at Your Pharmacy
IBS Don't Be Surprised to See Zelnorm Return to Your Inventory

Stay Alert for Safety Issues With Xeljanz and Other "JAK Inhibitors"

Practical advice for a better career, with unlimited access to CE

Table of Contents